Text Size

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study

Ansari E., Pavicic-Astalos J., Ayan F., King A.J., Kinsella M., Ng E., Nita A., The VISIONARY Group


  • 2021
  • Advances in Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Ansari, E., Maidstone and Tunbridge Wells NHS Trust, University of Kent at Canterbury, Kent, United Kingdom; Pavicic-Astalos, J., Institute of Eye Surgery, UPMC Whitfield, Waterford, Ireland; Ayan, F., Santen UK Ltd, St Albans, United Kingdom; King, A.J., Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Kinsella, M., Buckinghamshire Healthcare NHS Trust, Stoke Mandeville Hospital, Aylesbury, Buckinghamshire, United Kingdom; Ng, E., Institute of Eye Surgery, UPMC Whitfield, Waterford, Ireland; Nita, A., Royal Victoria Infirmary, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; The VISIONARY Group

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.


Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.


Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022